Graves' disease Graves' disease, hyperthyroidism, total thyroidectomy, cholesterol, lipid metabolism
Conditions
Interventions
No study-specific intervention will be performed. This is an observational study. Total thyroidectomy, preoperative treatment, postoperative levothyroxine replacement, and lipid management will be per
Not applicable
Sponsors
Tomiie Yumi
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients who provide written informed consent after receiving sufficient explanation and understanding the study. 2. Patients aged 18 years or older at the time of informed consent. 3. Patients clinically diagnosed with Graves disease and scheduled to undergo elective total thyroidectomy. 4. Patients considered able to be followed until 6 months after surgery as part of routine clinical care.
Exclusion criteria
Exclusion criteria: 1. Patients receiving lipid-lowering drugs at the time of enrollment. 2. Patients diagnosed with primary dyslipidemia, such as familial hypercholesterolemia. 3. Patients with comorbidities considered to have a major influence on lipid metabolism, such as nephrotic syndrome, active liver disease, or severe renal dysfunction. 4. Pregnant or breastfeeding patients. 5. Patients with thyroid storm. 6. Patients requiring emergency surgery. 7. Patients judged by the principal investigator or subinvestigators to be unsuitable for participation in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in LDL cholesterol level from immediately before surgery to 6 months after surgery. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Changes in lipid parameters from enrollment to immediately before surgery. 2. Changes in lipid parameters at 1, 3, and 6 months after surgery. 3. Longitudinal changes in lipid parameters. 4. Proportion of patients with dyslipidemia at 6 months after surgery. 5. Changes in body weight and body mass index. 6. Changes in thyroid function. 7. Association between preoperative treatment and changes in lipid parameters. 8. Proportion of patients who newly start lipid-lowering therapy after surgery. 9. Exploratory assessment at 12 months after surgery, if data are available in routine clinical care. | — |
Contacts
Public ContactYumi Tomiie
Fujita Health University School of Medicine
Outcome results
None listed